UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------
FORM 6-K
------------
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
The Securities Exchange Act of 1934
September 26, 2007
------------
CRUCELL NV
(Exact name of registrant as specified in its charter)
P.O. BOX 2048 ARCHIMEDESWEG 4 2333 CN LEIDEN THE NETHERLANDS
(Address of principal executive offices)
000-30962
(Commission File Number)
------------
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F:
Form 20-F [X] Form 40-F [ ]
Indicate by check mark whether the registrant by furnishing the information
contained in this form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes [ ] No [X]
CORRECTION - IMPACT OF DISCONTINUATION OF MERCK HIV STUDY ON CRUCELL'S PROSPECTS
LEIDEN, THE NETHERLANDS, SEPTEMBER 25 2007 - Dutch biotechnology company Crucell
N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) today stated that it wishes
to emphasize that the discontinuation of Merck's HIV phase I and II studys, as
announced on Friday September 21, is not related to the use of Crucell's
PER.C6(R) technology. The company further added that it reiterates its revenue
guidance for 2007 at (euro) 220 to 225 million.
"While the vaccine is produced on Crucell's PER.C6(R) technology, the
discontinuation of the study appears in no way related to the safety or efficacy
of the PER.C6(R) production technology and therefore has no impact on either
Crucell's licensing activities or Crucell's partnership with Merck with respect
to Crucell's PER.C6(R) and Advac(R) technologies as announced two weeks ago",
said Dr. Jaap Goudsmit, Crucell's Chief Scientific Officer. "We emphathize with
all people at risk of AIDS for whom this result is a set back."
Crucell also reiterates its revenue guidance of (euro) 220-225 million for 2007.
"We had not incorporated any income from the Merck HIV program in our guidance
for 2007. As the program was in a phase II study it was not at all expected to
enter the market within the next couple of years to generate royalty-based
income for Crucell. We therefore wish to emphasize that our guidance for 2007
has not changed as a result of this event," said Ronald Brus, Chief Executive
Officer. "Bringing an HIV vaccine to market has always been considered to be a
major challenge."
ABOUT CRUCELL
Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology
company focused on research, development and worldwide marketing of vaccines and
antibodies that prevent and treat infectious diseases. Its vaccines are sold in
public and private markets worldwide. Crucell's core portfolio includes a
vaccine against hepatitis B, a fully-liquid vaccine against five important
childhood diseases, and a virosome-adjuvanted vaccine against influenza. Crucell
also markets travel vaccines, such as the only oral anti-typhoid vaccine, an
oral cholera vaccine and the only aluminium-free hepatitis A vaccine on the
market. The Company has a broad development pipeline, with several Crucell
products based on its unique PER.C6(R) production technology. The Company
licenses this and other technologies to the biopharmaceutical industry.
Important partners and licensees include DSM Biologics, sanofi aventis, GSK and
Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with
subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the US. The Company
employs over a 1000 people. For more information, please visit www.crucell.com.
FOR FURTHER INFORMATION PLEASE CONTACT:
MEDIA: INVESTORS/ANALYSTS:
Barbara Mulder Oya Yavuz
Director Corporate Director Investor
Communications Relations
Tel: +31-(0) 71-519 7346 Tel. +31-(0) 71-519
press@crucell.com 7064
ir@crucell.com
SIGNATURES
Pursuant to the requirements of the Securities Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
CRUCELL NV
-----------------------------------------
(Registrant)
September 26, 2007 /s/ LEON KRUIMER
- ------------------------ -----------------------------------------
(Date) Leon Kruimer
Chief Financial Officer